DANBURY, Conn., July 14, 2008 (PRIME NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has begun dosing in a Phase Ia clinical trial of A0001, a compound the Company is developing for the treatment of symptoms associated with mitochondrial diseases. Mitochondrial diseases are devastating illnesses that often occur during childhood and currently have no FDA approved treatments.
